Kalera Therapeutics Prices $625M IPO
Analysis based on 13 articles · First reported Apr 16, 2026 · Last updated Apr 16, 2026
The pricing of Kalera Therapeutics' IPO at $16.00 per share, raising $625.0 million, is expected to positively impact the biotechnology sector by bringing a new player focused on obesity care to the public market. This event provides a new investment opportunity for market participants and reflects investor confidence in the company's prospects.
Kalera Therapeutics, an advanced clinical-stage biotechnology company specializing in obesity care, announced the pricing of its initial public offering (IPO) of 39,062,500 shares of common stock at $16.00 per share. The offering is expected to generate gross proceeds of $625.0 million. Kalera Therapeutics' common stock is anticipated to begin trading on the Nasdaq Global Select Market under the ticker symbol 'KLRA' on April 17, 2026, with the offering closing on April 20, 2026. The company has also granted underwriters, including JPMorgan Chase===JPMorgan Chase, Jefferies Financial Group===Jefferies Group, Leerink Partners, Toronto-Dominion Bank===TD Cowen, Evercore===Evercore, and William Blair & Company, a 30-day option to purchase additional shares. The United States===United States Securities and Exchange Commission declared the registration statement for the offering effective.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard